Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer
| Status: | Terminated |
|---|---|
| Conditions: | Lung Cancer, Lung Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/17/2018 |
| Start Date: | February 2005 |
| End Date: | December 2010 |
Bone Metabolic Markers, TRAP, and Zometa's Effect on Bone Metastasis Due to Lung Cancer
The purpose of this study is to evaluate a new blood test as a way to follow the effect of
Zometa in treating bone metastases due to lung cancer.
Zometa in treating bone metastases due to lung cancer.
The purpose of this research study is to evaluate a new blood test as a way to follow the
effect of Zometa in treating bone metastases. The blood test will look for a protein, called
TRAP, which is released into the blood stream by the breakdown of bone. This study will
compare the TRAP blood test with other blood tests for bone destruction.
effect of Zometa in treating bone metastases. The blood test will look for a protein, called
TRAP, which is released into the blood stream by the breakdown of bone. This study will
compare the TRAP blood test with other blood tests for bone destruction.
Inclusion Criteria:
- invasive lung cancer (small cell or non-small cell lung cancer)
- osteolytic bone metastasis determined by clinical exam, bone scan/XR
- age > 18 years
Exclusion Criteria:
- concurrent malignancy with a second primary
- renal failure (serum creatinine > 3mg/dl)
- pregnancy
- active rheumatoid arthritis
- intolerance to zoledronic acid
We found this trial at
1
site
James Graham Brown Cancer Center No one should feel compelled to leave Kentucky to seek...
Click here to add this to my saved trials
